CD19 and plasma cell myeloma: At the present stage, six CAR-T cell products have been clinically approved: Yescarta (anti-CD19), Kymriah (anti-CD19), Tecartus (anti-CD19), Breyanzi (anti-CD19), Abecma (anti-BCMA), and Carvykti (anti-BCMA) for B cell malignancies and multiple myeloma [38–41].